Published in JAMA on July 02, 2008
The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis (2011) 16.88
HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med (2011) 6.30
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis (2015) 2.96
Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature (2009) 2.78
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials (2012) 2.71
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr (2010) 2.47
HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog (2014) 2.03
Untreated HIV: harmful even at high CD4 cell counts. Lancet (2010) 2.01
Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat (2011) 1.94
Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis (2012) 1.91
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis (2010) 1.79
Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr (2010) 1.67
Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr (2009) 1.54
Depression and Human Immunodeficiency Virus Infection Are Risk Factors for Incident Heart Failure Among Veterans: Veterans Aging Cohort Study. Circulation (2015) 1.43
Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One (2011) 1.42
Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol (2012) 1.39
Cardiovascular risk-factor knowledge and risk perception among HIV-infected adults. J Assoc Nurses AIDS Care (2013) 1.34
HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J (2011) 1.34
HIV infection and older Americans: the public health perspective. Am J Public Health (2012) 1.31
Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst (2010) 1.31
When to start antiretroviral therapy: the need for an evidence base during early HIV infection. BMC Med (2013) 1.30
The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review. AIDS Behav (2012) 1.28
Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS (2012) 1.26
AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. AIDS (2009) 1.17
Sexual orientation and mortality among US men aged 17 to 59 years: results from the National Health and Nutrition Examination Survey III. Am J Public Health (2011) 1.17
Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study. BMC Infect Dis (2013) 1.14
MACH14: a multi-site collaboration on ART adherence among 14 institutions. AIDS Behav (2013) 1.14
Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS One (2012) 1.13
Mortality by causes in HIV-infected adults: comparison with the general population. BMC Public Health (2011) 1.13
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med (2010) 1.12
Rural residence is associated with delayed care entry and increased mortality among veterans with human immunodeficiency virus infection. Med Care (2010) 1.10
Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother (2009) 1.09
Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis (2012) 1.08
Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS (2010) 1.06
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother (2008) 1.05
Th17, gut, and HIV: therapeutic implications. Curr Opin HIV AIDS (2010) 1.05
Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med (2013) 1.05
Timeliness of clinic attendance is a good predictor of virological response and resistance to antiretroviral drugs in HIV-infected patients. PLoS One (2012) 1.05
A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study. AIDS Res Hum Retroviruses (2012) 1.03
Initiation of antiretroviral therapy in youth with HIV: a U.S.-based provider survey. AIDS Patient Care STDS (2013) 1.02
Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors. Clin Infect Dis (2010) 1.01
Is the incidence of invasive vulvar cancer increasing in the United States? Cancer Causes Control (2009) 1.01
Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques. Antimicrob Agents Chemother (2014) 0.99
When to start antiretroviral therapy. Curr HIV/AIDS Rep (2010) 0.97
Antiretroviral treatment 2010: progress and controversies. J Acquir Immune Defic Syndr (2010) 0.96
Race, kidney disease progression, and mortality risk in HIV-infected persons. Clin J Am Soc Nephrol (2010) 0.95
Changes in first-line cART regimens and short-term clinical outcome between 1996 and 2010 in The Netherlands. PLoS One (2013) 0.94
Risk of Death among HIV Co-Infected Multidrug Resistant Tuberculosis Patients, Compared To Mortality in the General Population of South Africa. J AIDS Clin Res (2013) 0.91
State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors. J Gen Intern Med (2011) 0.90
Factors associated with cancer incidence and with all-cause mortality after cancer diagnosis among human immunodeficiency virus-infected persons during the combination antiretroviral therapy era. Open Forum Infect Dis (2014) 0.90
HIV testing practices among black primary care physicians in the United States. BMC Public Health (2013) 0.90
Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1. J Virol (2011) 0.90
Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China, 2003-2009. J Acquir Immune Defic Syndr (2013) 0.89
The burden of image based emphysema and bronchiolitis in HIV-infected individuals on antiretroviral therapy. PLoS One (2014) 0.87
Effect of baseline HIV disease parameters on CD4+ T cell recovery after antiretroviral therapy initiation in Kenyan women. PLoS One (2010) 0.87
Patterns, trends and sex differences in HIV/AIDS reported mortality in Latin American countries: 1996-2007. BMC Public Health (2011) 0.87
XVII International AIDS Conference: From Evidence to Action - Basic science. J Int AIDS Soc (2009) 0.86
Smoking Cessation Interventions in HIV-Infected Adults in North America: A Literature Review. J Addict Behav Ther Rehabil (2013) 0.86
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro. Antimicrob Agents Chemother (2010) 0.85
Focus Group Evaluation of the LIVE Network-An Audio Music Program to Promote ART Adherence Self-Management. Music Med (2012) 0.85
Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration. PLoS One (2013) 0.83
Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy. Crit Rev Immunol (2013) 0.83
Definition of advanced age in HIV infection: looking for an age cut-off. AIDS Res Hum Retroviruses (2012) 0.82
Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV. AIDS (2013) 0.82
Rural residence and adoption of a novel HIV therapy in a national, equal-access healthcare system. AIDS Behav (2013) 0.81
Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report. Oncologist (2010) 0.81
Pregnane X receptor mediates dyslipidemia induced by the HIV protease inhibitor amprenavir in mice. Mol Pharmacol (2013) 0.81
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study. BMC Public Health (2015) 0.81
Fatal cumulative toxicities of HAART in a stable, AIDS-free, HIV-infected patient. BMJ Case Rep (2012) 0.80
Routine HIV testing among hospitalized patients in Argentina. is it time for a policy change? PLoS One (2013) 0.80
Engagement-in-care during the first 5 years after HIV diagnosis: data from a cohort of newly HIV-diagnosed individuals in a large US city. AIDS Patient Care STDS (2014) 0.80
Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy. Antimicrob Agents Chemother (2015) 0.80
Provider and practice characteristics associated with use of rapid HIV Testing by general internists. J Gen Intern Med (2011) 0.80
A history of alcohol dependence augments HIV-associated neurocognitive deficits in persons aged 60 and older. J Neurovirol (2014) 0.79
Is arterial stiffness in HIV-infected individuals associated with HIV-related factors? Braz J Med Biol Res (2012) 0.79
A multicenter study of initiation of antiretroviral therapy and transmitted drug resistance in antiretroviral-naive adolescents and young adults with HIV in New York City. Clin Infect Dis (2014) 0.79
'Waiting at the dinner table for scraps': a qualitative study of the help-seeking experiences of heterosexual men living with HIV infection. BMJ Open (2012) 0.79
Routine HIV testing hits the primary care clinic. J Gen Intern Med (2009) 0.79
Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infection. J Infect Dis (2012) 0.78
Psychosocial burdens negatively impact HIV antiretroviral adherence in gay, bisexual, and other men who have sex with men aged 50 and older. AIDS Care (2014) 0.78
Cost-effectiveness of enhanced syphilis screening among HIV-positive men who have sex with men: a microsimulation model. PLoS One (2014) 0.78
Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India. Indian J Med Res (2013) 0.77
Coinfection by Hepatitis C Is Strongly Associated with Abnormal CD4/CD8 Ratio in HIV Patients under Stable ART in Salvador, Brazil. J Immunol Res (2015) 0.77
PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study. J Transl Med (2014) 0.77
Animal models for viral infection and cell exhaustion. Curr Opin HIV AIDS (2014) 0.76
Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People? J Acquir Immune Defic Syndr (2016) 0.76
HIV-infected adolescent, young adult and pregnant smokers: important targets for effective tobacco control programs. Int J Environ Res Public Health (2013) 0.75
Need for improved access to HIV prevention programmes. Indian J Med Res (2010) 0.75
Multiple gaps in care common among newly diagnosed HIV patients. AIDS Care (2015) 0.75
Retinal Nerve Fiber and Optic Disc Morphology in Patients with Human Immunodeficiency Virus Using the Heidelberg Retina Tomography 3. PLoS One (2015) 0.75
The impact of HIV/AIDS on compliance with antidepressant treatment in major depressive disorder: A prospective study in a South African private healthcare cohort. AIDS Res Ther (2015) 0.75
When should antiretroviral therapy be started in HIV-positive persons? F1000 Med Rep (2010) 0.75
Trends in hospital deaths among human immunodeficiency virus-infected patients during the antiretroviral therapy era, 1995 to 2011. J Hosp Med (2015) 0.75
Mitral Annular and Coronary Artery Calcification Are Associated with Mortality in HIV-Infected Individuals. PLoS One (2015) 0.75
Managing drug interactions in HIV-infected adults with comorbid illness. CMAJ (2014) 0.75
Oral prednisolone for preschool children with acute virus-induced wheezing. N Engl J Med (2009) 7.24
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14
What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med (2004) 5.67
Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ (2010) 5.60
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A (2007) 4.96
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS (2007) 4.40
Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996-2005. Ann Epidemiol (2009) 4.36
Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet (2003) 3.84
HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis (2005) 3.77
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis. Lancet Infect Dis (2012) 3.26
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS (2006) 3.23
Increasing prevalence of male homosexual partnerships and practices in Britain 1990-2000: evidence from national probability surveys. AIDS (2004) 3.17
Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med (2012) 3.12
Methodology of the third British National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Sex Transm Infect (2013) 3.08
Scale-free networks and sexually transmitted diseases: a description of observed patterns of sexual contacts in Britain and Zimbabwe. Sex Transm Dis (2004) 2.75
Ethnic variations in sexual behaviour in Great Britain and risk of sexually transmitted infections: a probability survey. Lancet (2005) 2.64
Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ (2008) 2.63
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60
Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One (2013) 2.55
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ (2005) 2.51
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45
Sexual risk behaviour and knowledge of HIV status among community samples of gay men in the UK. AIDS (2008) 2.43
Missed opportunities for earlier HIV diagnosis within primary and secondary healthcare settings in the UK. AIDS (2008) 2.34
Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines. Clin Infect Dis (2011) 2.30
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. Lancet (2003) 2.27
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21
Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol (2009) 2.17
Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One (2008) 2.14
Bivariate random-effects meta-analysis and the estimation of between-study correlation. BMC Med Res Methodol (2007) 2.13
Sexual function problems and help seeking behaviour in Britain: national probability sample survey. BMJ (2003) 2.12
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Who has sex with whom? Characteristics of heterosexual partnerships reported in a national probability survey and implications for STI risk. Int J Epidemiol (2008) 2.06
Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis (2009) 2.03
Screening and cervical cancer cure: population based cohort study. BMJ (2012) 1.99
The prevalence of unplanned pregnancy and associated factors in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Lancet (2013) 1.91
Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol (2008) 1.90
Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis (2004) 1.85
Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. AIDS (2010) 1.82
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Sexual function in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Lancet (2013) 1.77
Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS (2005) 1.75
Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol (2007) 1.74
Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. J Clin Epidemiol (2005) 1.72
The Regai Dzive Shiri Project: a cluster randomised controlled trial to determine the effectiveness of a multi-component community-based HIV prevention intervention for rural youth in Zimbabwe--study design and baseline results. Trop Med Int Health (2008) 1.70
A population-based comparison of the survival of patients with colorectal cancer in England, Norway and Sweden between 1996 and 2004. Gut (2011) 1.70
Associations between health and sexual lifestyles in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Lancet (2013) 1.67
Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies. PLoS Med (2010) 1.65
The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS (2011) 1.65
Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Stat Med (2008) 1.65
Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? Clin Infect Dis (2005) 1.64
Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood (2011) 1.62
Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. J Acquir Immune Defic Syndr (2003) 1.59
Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS (2010) 1.57
Reported sexually transmitted disease clinic attendance and sexually transmitted infections in britain: prevalence, risk factors, and proportionate population burden. J Infect Dis (2005) 1.53
Estimating the regional distribution of men who have sex with men (MSM) based on Internet surveys. BMC Public Health (2009) 1.51
Comparison of in vitro cell culture and a mouse assay for measuring infectivity of Cryptosporidium parvum. Appl Environ Microbiol (2002) 1.51
Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis (2011) 1.50
Contamination during production of heater-cooler units by Mycobacterium chimaera potential cause for invasive cardiovascular infections: results of an outbreak investigation in Germany, April 2015 to February 2016. Euro Surveill (2016) 1.48
A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res (2004) 1.47
Late presenters in an HIV surveillance system in Italy during the period 1992-2006. J Acquir Immune Defic Syndr (2008) 1.47
The Regai Dzive Shiri project: results of a randomized trial of an HIV prevention intervention for youth. AIDS (2010) 1.47
Communicable diseases prioritized for surveillance and epidemiological research: results of a standardized prioritization procedure in Germany, 2011. PLoS One (2011) 1.45
Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. J Infect Dis (2007) 1.44
Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr (2003) 1.44
A general framework for parametric survival analysis. Stat Med (2014) 1.43
Is the level of proof of the North American multicohort collaboration prospective study sufficient to conclude that incidence of invasive cervical cancer is higher in HIV-infected women? J Acquir Immune Defic Syndr (2013) 1.42